bluebird bio (BLUE) PT Lowered to $14 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Goldman Sachs Downgrades bluebird bio (BLUE) to Sell
November 8, 2021 7:38 AM ESTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Neutral to Sell with a price target of $10.00 (from $23.00).
The analyst comments "We downgrade BLUE to Sell from Neutral and lower our 12-month PT to $10 from $23. Post the separation of the severe genetic disease (SGD; BLUE) and oncology businesses (2seventy bio; TSVT), BLUE is focused on developing and... More
